MAXIMUS, Inc. (MMS) Stake Lessened by Cambiar Investors LLC

Share on StockTwits

Cambiar Investors LLC lowered its position in MAXIMUS, Inc. (NYSE:MMS) by 0.6% during the first quarter, according to its most recent filing with the SEC. The firm owned 70,143 shares of the health services provider’s stock after selling 451 shares during the period. Cambiar Investors LLC’s holdings in MAXIMUS were worth $4,979,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of MMS. Oregon Public Employees Retirement Fund lifted its position in shares of MAXIMUS by 6,329.9% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,656,085 shares of the health services provider’s stock worth $25,000 after purchasing an additional 1,630,329 shares during the period. Norges Bank acquired a new position in shares of MAXIMUS in the 4th quarter worth approximately $49,088,000. Virginia Retirement Systems ET AL lifted its position in shares of MAXIMUS by 1,483.2% in the 1st quarter. Virginia Retirement Systems ET AL now owns 310,300 shares of the health services provider’s stock worth $22,025,000 after purchasing an additional 290,700 shares during the period. Mackenzie Financial Corp lifted its position in shares of MAXIMUS by 17.6% in the 4th quarter. Mackenzie Financial Corp now owns 1,853,213 shares of the health services provider’s stock worth $120,626,000 after purchasing an additional 277,775 shares during the period. Finally, Ranger Investment Management L.P. lifted its position in shares of MAXIMUS by 113.2% in the 4th quarter. Ranger Investment Management L.P. now owns 467,032 shares of the health services provider’s stock worth $30,399,000 after purchasing an additional 248,002 shares during the period. Hedge funds and other institutional investors own 95.81% of the company’s stock.

A number of brokerages have recently issued reports on MMS. Zacks Investment Research upgraded shares of MAXIMUS from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Wednesday, May 15th. ValuEngine downgraded shares of MAXIMUS from a “buy” rating to a “hold” rating in a research report on Thursday, February 28th.

MAXIMUS stock opened at $72.89 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.31 and a current ratio of 2.31. MAXIMUS, Inc. has a 12-month low of $60.00 and a 12-month high of $74.18. The firm has a market cap of $4.56 billion, a P/E ratio of 21.44, a P/E/G ratio of 1.93 and a beta of 0.96.

MAXIMUS (NYSE:MMS) last released its earnings results on Thursday, May 9th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.05. MAXIMUS had a net margin of 8.76% and a return on equity of 21.19%. The company had revenue of $736.50 million for the quarter, compared to the consensus estimate of $757.29 million. During the same quarter in the previous year, the company earned $0.84 EPS. MAXIMUS’s quarterly revenue was up 20.2% compared to the same quarter last year. On average, equities research analysts expect that MAXIMUS, Inc. will post 3.71 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, May 31st. Investors of record on Wednesday, May 15th will be given a dividend of $0.25 per share. The ex-dividend date is Tuesday, May 14th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.37%. MAXIMUS’s payout ratio is presently 29.41%.

In related news, Director Russell A. Beliveau sold 1,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $71.40, for a total transaction of $71,400.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Vice Chairman Richard A. Montoni sold 12,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $70.69, for a total transaction of $848,280.00. Following the transaction, the insider now owns 412,874 shares in the company, valued at approximately $29,186,063.06. The disclosure for this sale can be found here. Insiders have sold a total of 48,000 shares of company stock worth $3,403,630 in the last quarter. 2.20% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “MAXIMUS, Inc. (MMS) Stake Lessened by Cambiar Investors LLC” was reported by Zolmax and is owned by of Zolmax. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://zolmax.com/investing/maximus-inc-mms-stake-lessened-by-cambiar-investors-llc/3092547.html.

MAXIMUS Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs worldwide. The company's Health Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews.

See Also: 52-Week High/Low Prices For Stock Selection

Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MAXIMUS, Inc. (NYSE:MMS).

Institutional Ownership by Quarter for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Goldman Sachs BDC Inc  Receives Average Recommendation of “Hold” from Brokerages
Goldman Sachs BDC Inc Receives Average Recommendation of “Hold” from Brokerages
Analysts Set Daily Mail and General Trust P L C  Price Target at $685.57
Analysts Set Daily Mail and General Trust P L C Price Target at $685.57
Novocure Ltd  Receives $52.00 Consensus Target Price from Brokerages
Novocure Ltd Receives $52.00 Consensus Target Price from Brokerages
PetIQ Inc  Given Average Rating of “Buy” by Analysts
PetIQ Inc Given Average Rating of “Buy” by Analysts
Banco Santander SA  Receives Average Recommendation of “Buy” from Brokerages
Banco Santander SA Receives Average Recommendation of “Buy” from Brokerages
Precision Drilling Corp  Receives Average Recommendation of “Buy” from Analysts
Precision Drilling Corp Receives Average Recommendation of “Buy” from Analysts


 
© 2006-2019 Zolmax.